Loading…
Virax Biolabs Group Limited is projected to decline to $2.84 by 2027, a -3% move from its current price of $2.94. VRAX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $2.71 | $2.94 | $3.19 | -0.06% |
| Aug 6 | $2.62 | $2.94 | $3.29 | -0.13% |
| Aug 7 | $2.55 | $2.93 | $3.38 | -0.19% |
| Aug 8 | $2.49 | $2.93 | $3.45 | -0.25% |
| Aug 9 | $2.44 | $2.93 | $3.52 | -0.32% |
| Aug 10 | $2.40 | $2.93 | $3.58 | -0.38% |
| Aug 11 | $2.36 | $2.93 | $3.63 | -0.44% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.36 | $2.93 | $3.63 | -0.44% |
| Week 2 | $2.15 | $2.91 | $3.95 | -0.88% |
| Week 3 | $2.00 | $2.90 | $4.21 | -1.32% |
| Week 4 | $1.88 | $2.89 | $4.45 | -1.76% |
| Week 5 | $1.78 | $2.88 | $4.66 | -2.19% |
| Week 6 | $1.69 | $2.86 | $4.85 | -2.62% |
| Week 7 | $1.61 | $2.85 | $5.04 | -3.05% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Virax Biolabs Group Limited is a biotechnology company focused on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China.
It offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease. It also provides ImmuneSelect, a research-use-only portfolio of peptide pool ELISpot plates and related immune reagents, and engages in research and development activities and related services.
Founded in 2013 and headquartered in Lanarkshire, United Kingdom, the company was formerly known as Virax Biolabs (Cayman) Limited and renamed Virax Biolabs Group Limited in September 2021. It serves research organizations, academic institutions, contract research organizations, biopharmaceutical companies, independent laboratories, and distributors.
Virax Biolabs Group Limited trades at $2.62 per share, with a market capitalization of $2.09M. It is currently ranked 5436.
The 50-day simple moving average is $4.22 and the 200-day simple moving average is $6.92, indicating the price is below longer-term benchmarks.
Forecasts show a mixed path through the coming years, with 2026 averaging $2.62 and turning more positive later in the horizon. The 2040 and 2050 projections yield averages of $4.36 and $4.71 respectively, with notable upside of 66.5% and 79.6% in those years, after a period of weaker performance earlier in the forecast.
A major floor 96.5% below — a decisive break under it would weaken the trend.
The nearest floor, 10.9% below — buyers have tended to step in here.
The nearest ceiling, 116.3% above — a clean break opens room to run.
A major ceiling 215.1% above — clearing it would confirm fresh momentum.
Key VRAX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VRAX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.87 | Buy | $2.87 | Buy |
| MA 10 | $3.21 | Sell | $3.08 | Sell |
| MA 20 | $3.54 | Sell | $3.04 | Sell |
| MA 50 | $1.82 | Buy | $2.22 | Buy |
| MA 100 | $0.9919 | Buy | $1.48 | Buy |
| MA 200 | $0.6898 | Buy | $1.07 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.01 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -112.48 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.25 | Sell |
| ROC (12) | -24.06 | Sell |
| Bollinger %B (20,2) | 0.20 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 3.28 | Buy |
| Awesome (5,34) | 0.30 | Buy |
| Ultimate (7,14,28) | 17.05 | Buy |
| Momentum (10) | -1.17 | Sell |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 2.64 | Buy |
| ADX (14) | 21.04 | Sell |
| ATR (14) | 0.29 | Info |
Sentiment is BEARISH with RSI(14) at 40. The price sits below the 50-day SMA of $4.22 and the 200-day SMA of $6.92. Key near-term support is at $2.62 and resistance at $6.36.
The 30-day price range runs from $1.53 to $4.48, and annualized volatility is 200%.,
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.60 | $2.94 | $3.33 | 0% | Neutral | |
| $2.07 | $2.84 | $4.21 | -3% | Neutral | |
| $1.61 | $2.36 | $3.73 | -20% | Bearish | |
| $1.34 | $2.06 | $3.43 | -30% | Bearish | |
| $1.33 | $2.15 | $3.72 | -27% | Bearish | |
| $1.37 | $2.30 | $4.13 | -22% | Bearish | |
| $1.80 | $3.17 | $5.87 | +8% | Neutral | |
| $1.83 | $3.35 | $6.37 | +14% | Neutral | |
| $1.63 | $3.11 | $6.05 | +6% | Neutral | |
| $1.61 | $3.18 | $6.35 | +8% | Neutral | |
| $2.21 | $4.90 | $10.75 | +67% | Bullish | |
| $2.37 | $5.27 | $12.13 | +79% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.60 | $2.94 | $3.41 | +0.00% |
| September 2026 | $2.26 | $2.74 | $3.48 | -6.69% |
| October 2026 | $2.25 | $2.78 | $3.59 | +1.15% |
| November 2026 | $2.09 | $2.61 | $3.43 | -6.00% |
| December 2026 | $1.98 | $2.50 | $3.33 | -4.19% |
Click any year to see its month-by-month VRAX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Virax Biolabs Group Limited's 2026 outlook centres on $2.94, within a $2.60 to $3.33 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, VRAX could reach as high as $4.21, with a base case around $2.84 and support toward $2.07 — roughly -3% from $2.94. A consolidation phase looks the most probable path here.
Expect VRAX to range from $1.61 to $3.73 through 2028. The $2.36 average target implies a -20% move from current prices. That is -17% versus the projected 2027 average. A cyclical pullback looks likely — prices rarely move in a straight line.
The VRAX price prediction for 2029 points to an average of $2.06 (low $1.34, high $3.43) — a potential decline of -30% on today's $2.94. Expect choppier, lower action through this leg of the cycle.
In 2030, VRAX is projected to trade between $1.33 and $3.72, averaging $2.15 — a potential decline of -27% from today's $2.94. That is up +4% on the projected 2029 average. A cyclical pullback looks likely — prices rarely move in a straight line.
Virax Biolabs Group Limited's 2031 outlook centres on $2.30, within a $1.37 to $4.13 range. That is up +7% on the projected 2030 average. That marks a -22% change versus current levels. Expect choppier, lower action through this leg of the cycle.
By 2032, VRAX could reach as high as $5.87, with a base case around $3.17 and support toward $1.80 — roughly +8% from $2.94. Price action looks broadly range-bound.
Expect VRAX to range from $1.83 to $6.37 through 2033. The $3.35 average target implies a +14% move from current prices. That is up +6% on the projected 2032 average. A consolidation phase looks the most probable path here.
The VRAX price prediction for 2034 points to an average of $3.11 (low $1.63, high $6.05) — a potential gain of +6% on today's $2.94. Price action looks broadly range-bound.
In 2035, VRAX is projected to trade between $1.61 and $6.35, averaging $3.18 — a potential gain of +8% from today's $2.94. That is up +2% on the projected 2034 average. A consolidation phase looks the most probable path here.
Virax Biolabs Group Limited's 2040 outlook centres on $4.90, within a $2.21 to $10.75 range. That is up +54% on the projected 2035 average. That marks a +67% change versus current levels. Momentum favours further upside here.
By 2050, VRAX could reach as high as $12.13, with a base case around $5.27 and support toward $2.37 — roughly +79% from $2.94. Buyers look set to stay in control over this stretch.
Investing $1,000 in VRAX today (≈ 340.136054 VRAX) could be worth
$1,793.19
+$793.19 (+79%) by 2050 · US Dollar
Based on the average projected VRAX price of $5.27 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VRAXwould be worth at today's price.
$1,000 invested in VRAX on Jul 31, 2025 (≈ 1,234.567898 VRAX) would be worth
$3,629.63
+$2,629.63 (+263.0%) today · 3.63× · US Dollar
Based on a VRAX entry price of $0.81 vs. today's $2.94.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.19 | $921.63 | -7.8% |
| 1 month ago | $2.74 | $1,072.99 | +7.3% |
| 3 months ago | $0.132 | $22,272.73 | +2127.3% |
| 6 months ago | $0.272 | $10,808.82 | +980.9% |
| 1 year ago | $0.81 | $3,629.63 | +263.0% |
| All time (4.0y) ago | $182 | $16.15 | -98.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VRAX forecast.
$5.90 is within our bullish range by 2033, but above the base case.
Implied market cap at $5.90: $4.7M
The multi-year forecast shows a challenging start in the near term, with 2026 averaging $2.62 and 2027 averaging $2.54 (ROI -3.2%), followed by continued weakness into 2029 (avg $1.83; ROI -30%) and 2030 (avg $1.92; ROI -26.8%). This reflects a sustained bearish tone through 2031 (avg $2.05; ROI -21.8%).
From 2032 onward, sentiment shifts to neutral with 2032 averaging $2.83 (ROI 8%), then 2033 at $2.99 (ROI 14.1%), 2034 at $2.76 (ROI 5.4%), and 2035 at $2.84 (ROI 8.5%).
In the long horizon, the outlook turns bullish: 2040 averages $4.36 (ROI 66.5%), and 2050 averages $4.71 (ROI 79.6%). These estimates imply meaningful upside later in the forecast, with higher potential prices in the 2040s and beyond, but they come with substantial uncertainty and are not guarantees.
Tap a question to reveal the answer.
2030 avg $1.92, min $1.19, max $3.32, ROI -26.8%, sentiment BEARISH.
Forecasts show a mix of outcomes: early years include neutral to bearish results (e.g., 2026 avg $2.62, ROI 0%; 2028 avg $2.09, ROI -20.1%), with neutral to bullish potential emerging in 2032-2035 and stronger gains in 2040 (ROI 66.5%) and 2050 (ROI 79.6%). These are estimates, not guarantees.
Yes, the forecast maximum is $10.83 in 2050, with a 2050 average of $4.71.
RSI(14) = 40; sentiment BEARISH. SMA50 = $4.22, SMA200 = $6.92. Support at $2.62 and resistance at $6.36. The 30-day price range is $1.53 to $4.48; annualized volatility is 200%.
Current price $2.62; Market cap $2.09M; Rank 5436.
Virax Biolabs Group Limited Community Discussion
0Share your Virax Biolabs Group Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.